ASH 2022 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, Myeloma, VideosDecember 12, 2022
EMA recommends conditional marketing authorisation in Europe for teclistamab for relapsed and refractory myelomaAccess, MyelomaJuly 28, 2022
EHA 2021| Daratumumab plus lenalidomide and dexamethasone (D-Rd) shows overall survival benefit in elderly patients with transplant-ineligible newly diagnosed myelomaConferences, MyelomaJune 14, 2021
EHA 2021 | Daratumumab maintenance improves Progression-Free Survival (PFS) after autologous stem cell transplantation in myelomaConferences, MyelomaJune 13, 2021
EHA 2021 | Patient preferences in myeloma, a qualitative multinational study in myelomaConferences, MyelomaJune 11, 2021
European Commission approves the second indication of isatuximab for relapsed multiple myelomaAccess, MyelomaApril 19, 2021
